Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The outlook for the next fiscal year was prepared based on conservative estimates of the effects of emergency measures to improve earnings and expenses, at a level considered highly achievable.
Impairment losses of ¥720.512 million. The company stated that it recorded impairment losses of ¥360.600 million in the regenerative medicine-related business and ¥160.980 million in the AI and technology business.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥2,863 million（+20.8%） |
| Operating profit | Not disclosed → ¥-213 million |
| Ordinary income | Not disclosed → ¥-223 million |
| Profit attributable to owners of the parent | Not disclosed → ¥-246 million |
| Net income per share | Not disclosed → -2.97 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Fiscal year ended March 2026: net sales of ¥2,370 million, operating loss of ¥774 million, ordinary loss of ¥961 million, net loss attributable to owners of the parent of ¥1,276 million, and net loss per share of ¥16.52 |
| Reason for the revision | The outlook for the next fiscal year was prepared based on conservative estimates of the effects of emergency measures to improve earnings and expenses, at a level considered highly achievable. |
| Details and amount of extraordinary loss | Impairment losses of ¥720.512 million. The company stated that it recorded impairment losses of ¥360.600 million in the regenerative medicine-related business and ¥160.980 million in the AI and technology business. |
| Dividend forecast revision | For the fiscal year ending March 2027, the forecast dividend is ¥0.00 per share at the end of the second quarter, ¥0.00 per share at fiscal year-end, and ¥0.00 per share for the full year. The explicit statement “There is no revision to the dividend forecast” is Not disclosed. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, the sales impact of new products fell short of expectations, while selling expenses, advertising expenses, research and development expenses and depreciation and amortization increased. Delays in the supply chain and order fulfillment, along with weak performance in the events business, also contributed. In addition, impairment losses were recorded in the regenerative medicine-related business and the AI and technology business. The forecast for the fiscal year ending March 2027 was prepared based on conservative estimates of the effects of emergency measures to improve earnings and expenses, at a level considered highly achievable.